Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4.
No abstract available

Keywords: Cancer; Immunology; Oncology; P53; T cells.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Antigens, Neoplasm* / genetics
  • Antigens, Neoplasm* / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / pathology
  • Female
  • HLA-A2 Antigen* / genetics
  • HLA-A2 Antigen* / immunology
  • HLA-DP beta-Chains* / genetics
  • HLA-DP beta-Chains* / immunology
  • Humans
  • Male
  • Mice
  • Mutation*
  • Neoplasms, Glandular and Epithelial* / genetics
  • Neoplasms, Glandular and Epithelial* / immunology
  • Neoplasms, Glandular and Epithelial* / pathology
  • Tumor Suppressor Protein p53* / genetics
  • Tumor Suppressor Protein p53* / immunology

Substances

  • Antigens, Neoplasm
  • HLA-A*02:01 antigen
  • HLA-A2 Antigen
  • HLA-DP beta-Chains
  • HLA-DPB1 antigen
  • TP53 protein, human
  • Tumor Suppressor Protein p53

Associated data

  • ClinicalTrials.gov/NCT01174121
  • ClinicalTrials.gov/NCT02133196
  • ClinicalTrials.gov/NCT01585428